中国肺癌杂志Issue(10)：519-523,5.DOI:10.3779/j.issn.1009-3419.2013.10.04
苹果酸舒尼替尼治疗多次复发的晚期非小细胞肺癌疗效与安全性分析
Efifcacy and Safety of Albumin-bound Paclitaxel in Treating Recurrent Advanced Non-small Cell Lung Cancer
摘要
Abstract
Background and objective Advanced non-small cell lung cancer (NSCLC) is a common malignancy that is incurable. No standard treatment exists for recurrent patients. hTis article analyzed the effcacy and safety of sunitinib (37.5 mg qd) on a continuous daily dosing (CDD) schedule in treating recurrent advanced NSCLC. Methods We retrospec-tively analyzed the short-term effcacy and toxicity of sunitinib CDD in treating 17 patients who had previously undergone multiple cycles of therapy for advanced NSCLC in our hospital from January 2011 to December 2012. Treatment-related survival was also analyzed. Results Among the 17 patients, the best overall response was partial response in 1 patient (5.9%), stable disease in 7 patients (41.2%), and progressive disease in 9 patients (52.9%). hTe overall response rate was 5.9%, and the disease control rate was 47.1%. hTe median progression-free survival was 4.4 months (95%CI:4.05-7.46). hTe main grade 3/4 toxicity was hand-foot skin reaction. Conclusion Sunitinib (37.5 mg QD) CDD enabled good objective response in advanced NSCLC patients who had previously received multiple cycles of treatment and was well tolerated.关键词
肺肿瘤/苹果酸舒尼替尼/复发/酪氨酸激酶抑制剂Key words
Lung neoplsms/Sunitinib/Recurrence/Tyrosine kinase inhibitors引用本文复制引用
邢镨元,李峻岭,石远凯..苹果酸舒尼替尼治疗多次复发的晚期非小细胞肺癌疗效与安全性分析[J].中国肺癌杂志,2013,(10):519-523,5.基金项目
本研究受国家“重大新药创制”科技重大专项“十一?五”课题（No.2008ZX09312-020）；国家“重大新药创制”科技重大专项“十二?五”课题（No.2012ZX09303-012）；北京市科技计划项目（No. Z111102071011001）；中央保健课题（No.B2009B124）资助 （）
